Will GlaxoSmithKline plc Be Back To Growth By 2016?

Growth at GlaxoSmithKline plc (LON: GSK) has been slipping, but it should be back soon.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

A few years ago GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) was looking stronger than rival AstraZeneca, with its more promising pipeline and better acquisition strategy offering better protection from the loss of patent protection on key drugs.

But that’s been turned on its head since Pascal Soriot joined and revamped AstraZeneca, so what are the prospects like now for future growth at Glaxo?

After a couple of years of pretty much no change in earnings per share (EPS) from GlaxoSmithKline, there’s a hefty drop of 17% forecast for the year ending December 2014, and this close to year-end it’s unlikely to be far out.

Strong pound

At third-quarter time, core earnings per share came in 14% down at actual exchange rates, but at constant exchange rates the figure was only minus 2%. Like many multinationals reporting in Sterling, GlaxoSmithKline is suffering from the effects of a strong pound. But the firm expects “full year 2014 core EPS to be broadly similar to 2013” at constant exchange, suggesting that the business itself is really not that far off growth.

The Q3 dividend was held steady at 19p per share, but Glaxo expected to lift its full-year dividend as it has been doing year-on-year, and that lends more strength to its confidence in its longer-term growth potential.

Dividend forecasts suggest a yield of a very healthy 5.5% this year at today’s price levels of around 1,475p, and something very similar in 2015. But before we get too excited at that, it would be covered less than 1.2 times by forecast earnings for each of the two years.

Glaxo is clearly gearing its dividends to its expected future earnings growth, and there are strong signs we could be seeing that recovery coming very quickly, as the firm is in a period of intense restructuring that is expected to reduce costs by £1bn over three years — with half expecting to be realised by 2016.

The disposal of some non-core businesses looks set to continue too, which in the short term should raise some cash and in the longer term will hopefully beef up the company’s margins.

Growth worth buying?

What’s the price of that potential return to growth?

Well, Glaxo shares are on a year-end P/E of 16 dropping to 15.6 based on 2015 forecasts, and that’s only a little above the market average. On dividends alone that looks to be justified, but today’s yields won’t be sustainable unless that earnings growth really does get back on track.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »